Chicago and Miami Latest Airports to join CDC’s Nasal Swabbing Program
Six airports currently participate in the volunteer COVID detection tests.
covid test passport © Rudzhan - stock.adobe.com
Over 1 billion travelers visit U.S. airports every year. For this reason, airline passengers are one of the most important populations to consider when it comes to identifying and tracking COVID and other pathogens.
The Traveler-based Genomic Surveillance Program (TGS), which is led by the Centers for Disease Control and Prevention’s (CDC) Travelers’ Health Branch has been collecting nasal swabs from international travelers since 2021. It currently operates at six airports in the U.S.
The CDC announced Tuesday that it will be adding Chicago O’Hare International Airport and Miami International Airport to its list of locations that participate in the program.
International travelers who wish to participate can stop at a testing station after their flight to self-administer a nasal swab and complete an anonymous, short survey about their trip. Samples are then sent to a laboratory where they undergo genome sequencing to detect COVID variants and other respiratory pathogens.
The program currently operates at six U.S. airports:
- Seattle-Tacoma International Airport
- San Francisco International Airport
- Los Angeles International Airport
- John F. Kennedy International Airport
- Newark Liberty International Airport
- Dulles International Airport
Since it launched in Sept. 2021, TGS has enrolled roughly 300,000 travelers per year from over 135 countries.
In addition to nasal swabs, the CDC has also been collecting wastewater from airplanes since Aug. 2022. At Dulles International Airport, samples are taken directly from the plane. At Boston Logan International Airport and JFK, samples are collected from the airport triturator, which is the wastewater collection point for multiple aircraft.
The CDC says that wastewater collection is a low-cost method that removes the need to interact with travelers who are potentially carrying pathogens.
Overall, TGS has been an effective early warning system and was able to detect multiple Omicron variants up to six weeks before other agencies in the U.S.
Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI
November 19th 2024Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.
Listen
Leadership Team at The Cigna Group Revamps in Efforts to Drive Growth, Enhance Customer Focus
March 13th 2025David M. Cordani, chairman and CEO of The Cigna Group, expressed that these moves were made to “build upon our strengths for continued growth, enhance our customer focus, and deliver even greater value for those we serve."
Read More
In this latest episode of Tuning In to the C-Suite podcast, Briana Contreras, an editor with MHE had the pleasure of meeting Loren McCaghy, director of consulting, health and consumer engagement and product insight at Accenture, to discuss the organization's latest report on U.S. consumers switching healthcare providers and insurance payers.
Listen
Navitus to Offer Unbranded Stelara Biosimilar, Remove Stelara from Formulary
March 13th 2025Lumicera Health Services, Navitus’ specialty pharmacy, has made a deal with Teva to offer an unbranded biosimilar that they estimate will save $112,000 and $336,000 per patient per year. Navitus will remove Stelara from formulary on July 1, 2025.
Read More
